Effects of Statins on Cognitive Function in Patients with Alzheimer's Disease in Galantamine Clinical Trials

Overview

Journal Drugs Aging

Specialties Geriatrics
Pharmacology

Date 2007 Jan 20

PMID 17233547

Citations 8

Authors

Bengt Winblad

Vesna Jelic

Paul Kershaw

Joan Amatniek

Affiliations

Soon will be listed here.

Abstract

Background And Objective: A number of reports have been published on the possible involvement of changes in brain cholesterol metabolism in the origin of Alzheimer's disease (AD) and the potential for influencing these changes by administration of HMG-CoA reductase inhibitors ('statins'). The aim of this study was to evaluate a potential association between use of statins and maintenance of cognitive function in patients with AD in galantamine clinical trials.

Method: A post hoc analysis was conducted on data pooled from three double-blind, placebo-controlled, clinical trials of galantamine in patients with AD. Patients were divided into four treatment groups: statin plus galantamine (n = 42), statin alone (n = 50), galantamine alone (n = 614) or neither galantamine nor statin (n = 619).

Results: Galantamine was associated with a significant beneficial effect on cognitive status (p < 0.001). The association of use of statins with changes in cognitive status was not significant (p = 0.083). There was no significant interaction between the effects on cognition of statins and galantamine (p = 0.183) and no statistically significant changes in adverse effect rates were observed.

Conclusion: These findings suggest the need for larger long-term trials to confirm or refute possible effects of statins on cognitive function and the potential interaction of statins with acetylcholinesterase inhibitors in the treatment of AD.

Citing Articles

Overview the effect of statin therapy on dementia risk, cognitive changes and its pathologic change: a systematic review and meta-analysis.

Zhu X, Dai W, Ma T Ann Transl Med. 2019; 6(22):435.

PMID: 30596065 PMC: 6281522. DOI: 10.21037/atm.2018.06.43.

Impact on cognitive function-are all statins the same?.

Shah N, Swiger K, Martin S Curr Atheroscler Rep. 2014; 17(1):466.

PMID: 25398642 DOI: 10.1007/s11883-014-0466-5.

Treatment of vascular risk factors in patients with a diagnosis of Alzheimer's disease: a systematic review.

Valenti R, Pantoni L, Markus H BMC Med. 2014; 12:160.

PMID: 25385407 PMC: 4226862. DOI: 10.1186/s12916-014-0160-z.

Statins for the treatment of dementia.

McGuinness B, Craig D, Bullock R, Malouf R, Passmore P Cochrane Database Syst Rev. 2014; (7):CD007514.

PMID: 25004278 PMC: 11112650. DOI: 10.1002/14651858.CD007514.pub3.

Traditional Korean East Asian medicines and herbal formulations for cognitive impairment.

Kumar H, Song S, More S, Kang S, Kim B, Kim I Molecules. 2013; 18(12):14670-93.

PMID: 24287997 PMC: 6270158. DOI: 10.3390/molecules181214670.

References

Tariot P, Solomon P, Morris J, Kershaw P, Lilienfeld S, Ding C . A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology. 2000; 54(12):2269-76. DOI: 10.1212/wnl.54.12.2269. View

Jick H, Zornberg G, Jick S, Seshadri S, Drachman D . Statins and the risk of dementia. Lancet. 2000; 356(9242):1627-31. DOI: 10.1016/s0140-6736(00)03155-x. View

Refolo L, Malester B, Lafrancois J, Wang R, Tint G, Sambamurti K . Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis. 2000; 7(4):321-31. DOI: 10.1006/nbdi.2000.0304. View

Kirsch C, Eckert G, Koudinov A, Muller W . Brain cholesterol, statins and Alzheimer's Disease. Pharmacopsychiatry. 2003; 36 Suppl 2:S113-9. DOI: 10.1055/s-2003-43058. View

Knopp R . Drug treatment of lipid disorders. N Engl J Med. 1999; 341(7):498-511. DOI: 10.1056/NEJM199908123410707. View

Vega G, Weiner M, Lipton A, von Bergmann K, Lutjohann D, Moore C . Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease. Arch Neurol. 2003; 60(4):510-5. DOI: 10.1001/archneur.60.4.510. View

Eckert G, Wood W, Muller W . Statins: drugs for Alzheimer's disease?. J Neural Transm (Vienna). 2005; 112(8):1057-71. DOI: 10.1007/s00702-004-0273-1. View

Sparks D, Kuo Y, Roher A, Martin T, Lukas R . Alterations of Alzheimer's disease in the cholesterol-fed rabbit, including vascular inflammation. Preliminary observations. Ann N Y Acad Sci. 2000; 903:335-44. DOI: 10.1111/j.1749-6632.2000.tb06384.x. View

Wilcock G, Lilienfeld S, Gaens E . Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ. 2000; 321(7274):1445-9. PMC: 27547. DOI: 10.1136/bmj.321.7274.1445. View

10.

Scott H, Laake K . Statins for the prevention of Alzheimer's disease. Cochrane Database Syst Rev. 2001; (4):CD003160. DOI: 10.1002/14651858.CD003160. View

11.

Simons M, Schwarzler F, Lutjohann D, von Bergmann K, Beyreuther K, Dichgans J . Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol. 2002; 52(3):346-50. DOI: 10.1002/ana.10292. View

12.

. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002; 360(9326):7-22. DOI: 10.1016/S0140-6736(02)09327-3. View

13.

Gauthier S . Cholinergic adverse effects of cholinesterase inhibitors in Alzheimer's disease: epidemiology and management. Drugs Aging. 2002; 18(11):853-62. DOI: 10.2165/00002512-200118110-00006. View

14.

Wolozin B, Kellman W, Ruosseau P, CELESIA G, Siegel G . Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol. 2000; 57(10):1439-43. DOI: 10.1001/archneur.57.10.1439. View

15.

Crisby M, Carlson L, Winblad B . Statins in the prevention and treatment of Alzheimer disease. Alzheimer Dis Assoc Disord. 2002; 16(3):131-6. DOI: 10.1097/00002093-200207000-00001. View

16.

Rockwood K, Kirkland S, Hogan D, MacKnight C, Merry H, Verreault R . Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol. 2002; 59(2):223-7. DOI: 10.1001/archneur.59.2.223. View

17.

Shepherd J, Blauw G, Murphy M, Bollen E, Buckley B, Cobbe S . Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002; 360(9346):1623-30. DOI: 10.1016/s0140-6736(02)11600-x. View

18.

Lutjohann D, von Bergmann K . 24S-hydroxycholesterol: a marker of brain cholesterol metabolism. Pharmacopsychiatry. 2003; 36 Suppl 2:S102-6. DOI: 10.1055/s-2003-43053. View

19.

Kivipelto M, Helkala E, Laakso M, Hanninen T, Hallikainen M, Alhainen K . Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ. 2001; 322(7300):1447-51. PMC: 32306. DOI: 10.1136/bmj.322.7300.1447. View

20.

Raskind M, Peskind E, Wessel T, Yuan W . Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology. 2000; 54(12):2261-8. DOI: 10.1212/wnl.54.12.2261. View